Infectious complications in hairy cell leukemia

References

• Golomb HM, Hadad L. Infectious complications in 127 patients with hairy cell leukemia. Am J Hematol 1984;16:393–401.
   PubMed Web of Science ®Google Scholar
• Stewart DJ, Bodey GP. Infections in hairy cell leukemia. Cancer 1981;15:801–805.
   Web of Science ®Google Scholar
• Bouza E, Burgeleta C, Golde DW. Infections in hairy cell leukemia. Blood 1978:51 851–859.
   PubMed Web of Science ®Google Scholar
• Dasanu CA, Ichim TE, Alexandrescu DT. Inherent and iatrogenic immune defects in hairy cell leukemia revisited. Expert Opin Drug Saf 2010;9:55–59.
   PubMed Web of Science ®Google Scholar
• Grever M, Kopecky K, Foucar MK, et al. Randomized comparison of pentostatin and interferon alpha-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol 1995;4:974–982.
   Google Scholar
• Maloisel F, Benboubker L, Gardembas M, et al. Long term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients. Leukemia 2003;17:45–51.
   PubMed Web of Science ®Google Scholar
• Catovsky D, Matues E, Talavera JG, et al. Long term results with 2′deoxycoformycin in hairy cell leukemia. Leuk Lymphoma 1994;14(Suppl. 1):109–113.
   PubMed Web of Science ®Google Scholar
• Rafel M, Cervantes F, Beltran JM, et al. Deoxycoformycin in the treatment of patients with hairy cell leukemia: results of a Spanish collaborative study of 80 patients. Cancer 2000;88: 352–357.
   PubMed Web of Science ®Google Scholar
• Riberio, P, Bouaffia F, Peaud PY, et al. Long term outcome of patients treated with pentostatin. Cancer 1999;85:65–71.
   PubMed Web of Science ®Google Scholar
• Saven A, Burian C, Koziol JA, Piro LD. Long term followup of patients with hairy cell leukemia after treatment with cladribine. Blood 1998;92:1919–1926.
   Google Scholar
• Hoffman MA, Janson D, Rose E, Rai KR. Treatment of hairy cell leukemia with cladribine response, toxicity and long term followup. J Clin Oncol 1997;15:1138–1142.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Sorensen JM, Vena DA, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol 1998;16: 3007–3015.
   PubMed Web of Science ®Google Scholar
• Robak T, Blasinkra-Morawicc M, Blonski J, et al. 2-Chlorodeoxyadenosine in the treatment of hairy cell leukemia and hairy cell leukemia variant. Eur J Haemtol 1999; 62:49–56.
   PubMed Web of Science ®Google Scholar
• Tallman MS, Hakimian D, Variakojiis D, et al. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood 1992; 80:2203–2209.
   PubMed Web of Science ®Google Scholar
• Smith JW, Longo DL, Urba WJ, et al. Prolonged continuous treatment of hairy cell leukemia patients with recombinant interferon-α-2a. Blood 1991;78:1664–1671.
   PubMed Web of Science ®Google Scholar
• Benz R, Siciliano RD, Stussi G, Fehr J. Long term followup of interferon-alpha induction and low dose maintenance therapy in hairy cell leukemia. Eur J Haematol 2009;82:194–198.
   PubMed Web of Science ®Google Scholar
• Damasio EE, Clavio M, Masoudi B, et al. Alpha interferon as induction and maintenance therapy in hairy cell leukemia. Eur J Haemtol 2000;64:47–52.
   PubMed Web of Science ®Google Scholar
• Nieva J, Bethel K, Saven A. Phase II study of rituximab in the treatment of cladribine failed patients with hairy cell leukemia. Blood 2003;102:810–813.
   PubMed Web of Science ®Google Scholar
• Thomas D, O'Brien S, Bueso-Ramos C, et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood 2003;102: 3906–3911.
   PubMed Web of Science ®Google Scholar
• Hagberg H, Lundholm L. Rituximab, a chimaeric anti CD20 monoclonal antibody in the treatment of hairy cell leukemia Br J Haematol 2001;115:609–611.
   PubMed Web of Science ®Google Scholar
• Else M, Ruchlemer R, Osuji N, et al. Long remissions in patients with hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years. Cancer 2005;104:2442–2448.
   PubMed Web of Science ®Google Scholar
• Huynh E, Sigal D, Saven A. Cladribine in the treatment of hairy cell leukemia: initial and subsequent results Leuk Lymphoma 2009;50:12–17.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Kopecky KJ, Foucar KM, et al. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 2000;96:2981–2986.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Anderson JW, Cassileth PA, et al. Sequential administration of recombinant interferon alpha and deoxycoformycin in the treatment of hairy cell leukaemia. Br J Haematol 1992;80:466–471.
   PubMed Web of Science ®Google Scholar